Filgotinib

Abstract

Filgotinib is a novel JAK1 preferential inhibitor with high clinical and radiographic efficacy, a favorable safety and tolerability profile, and few drug-drug interactions. This review focuses on the results from basic research and clinical trials on filgotinib, which may have an impact on unmet needs in the treatment of rheumatoid arthritis, such as difficult-to-treat rheumatoid arthritis, rapid radiographic progression, precision medicine, JAK inhibitor cycling.